Despite dramatically improved survival rates for childhood acute lymphoblastic leukemia (ALL), relapse remains a leading cause of death from the disease. Researchers have now identified mutations in a gene named CREBBP that may help the cancer resist steroid treatment and fuel ALL’s return.